FDA approves ISEMBYLD as first muscle-targeted SMA therapy
ISEMBYLD has received FDA approval as the first muscle-targeted therapy for SMA, with a U.S. launch underway.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.